Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: ichihara e. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. Hrustanovic G, et al. Among authors: ichihara e. Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24. Nat Med. 2015. PMID: 26301689 Free PMC article.
Solar Neutrino Data Covering Solar Cycle 22.
Fukuda Y, Hayakawa T, Inoue K, Kasuga S, Koshio Y, Kumita T, Matsumoto K, Nakahata M, Nakamura K, Okumura K, Sakai A, Shiozawa M, Suzuki J, Suzuki Y, Tomoeda T, Totsuka Y, Hirata KS, Kihara K, Oyama Y, Koshiba M, Nishijima K, Horiuchi T, Fujita K, Hatakeyama S, Koga M, Maruyama T, Suzuki A, Mori M, Kajimura T, Suda T, Suzuki AT, Ishizuka T, Miyano K, Okazawa H, Hara T, Nagashima Y, Takita M, Yamaguchi T, Hayato Y, Kaneyuki K, Suzuki T, Takeuchi Y, Tanimori T, Tasaka S, Ichihara E, Miyamoto S, Nishikawa K. Fukuda Y, et al. Among authors: ichihara e. Phys Rev Lett. 1996 Aug 26;77(9):1683-1686. doi: 10.1103/PhysRevLett.77.1683. Phys Rev Lett. 1996. PMID: 10063145 No abstract available.
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, Nishii K, Shoda H, Yamaguchi K, Kawakado K, Toyoda Y, Inoue M, Miyatake N, Watanabe N, Inoue T, Mizoguchi H, Komori Y, Kojima K, Kadowaki N. Kanaji N, et al. Among authors: ichihara e. Lung. 2024 Feb;202(1):63-72. doi: 10.1007/s00408-023-00669-9. Epub 2024 Jan 24. Lung. 2024. PMID: 38265672 Free PMC article.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
158 results